- Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.
- DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for peripheral diseases.
- Denali will receive a $10 million clinical milestone payment from Sanofi.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing of DNL758, a peripherally restricted small molecule inhibitor of RIPK1, in a Phase 1 healthy volunteer study. This triggers a milestone payment of $10 million to Denali according to the Sanofi Collaboration Agreement for RIPK1 inhibitors.
RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. Denali and Sanofi are developing several molecules targeting RIPK1 inhibition, including DNL747 in neurological indications and DNL758 in several non-neurological indications.
“We believe that inhibition of RIPK1, a known target in the TNF pathway, has a compelling scientific rationale in autoimmune diseases,” said Ryan Watts, Ph.D., CEO. “While Denali will remain focused on defeating neurodegeneration, we are thrilled that our partner Sanofi has commenced clinical studies with DNL758, to investigate its potential in peripheral diseases.”
About Denali
Denali is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development with biomarker monitoring to demonstrate target engagement and select patients. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.
Post Views: 145
- Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.
- DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for peripheral diseases.
- Denali will receive a $10 million clinical milestone payment from Sanofi.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced that its partner Sanofi has commenced dosing of DNL758, a peripherally restricted small molecule inhibitor of RIPK1, in a Phase 1 healthy volunteer study. This triggers a milestone payment of $10 million to Denali according to the Sanofi Collaboration Agreement for RIPK1 inhibitors.
RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body. Denali and Sanofi are developing several molecules targeting RIPK1 inhibition, including DNL747 in neurological indications and DNL758 in several non-neurological indications.
“We believe that inhibition of RIPK1, a known target in the TNF pathway, has a compelling scientific rationale in autoimmune diseases,” said Ryan Watts, Ph.D., CEO. “While Denali will remain focused on defeating neurodegeneration, we are thrilled that our partner Sanofi has commenced clinical studies with DNL758, to investigate its potential in peripheral diseases.”
About Denali
Denali is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development with biomarker monitoring to demonstrate target engagement and select patients. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.
Post Views: 145
